Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
JUNS
Jupiter Neurosciences, Inc.
Direct product category: orally administered small-molecule therapeutics based on a resveratrol platform (JOTROL).
|
$36.92M |
$1.03
+0.49%
|
|
GBIO
Generation Bio Co.
Core business is developing RNA interference therapeutics (siRNA) targeting autoimmune diseases.
|
$36.91M |
$5.49
-0.36%
|
|
XCUR
Exicure, Inc.
GPCR USA's lead asset GPC-100.00 is an oncology biotech product in development, representing the core biotech asset.
|
$36.90M |
$5.79
-1.53%
|
|
VERU
Veru Inc.
Veru's lead asset enobosarm is an oral small molecule therapeutic.
|
$36.50M |
$2.49
+2.89%
|
|
NXTC
NextCure, Inc.
NextCure's lead programs are Antibody-Drug Conjugates (ADCs), the core product modality of the company.
|
$35.78M |
$13.05
-3.97%
|
|
OTLC
Oncotelic Therapeutics, Inc.
OT-101 is an antisense oligonucleotide targeting TGFB2, fitting the Oligonucleotide Therapeutics category.
|
$35.75M |
$0.09
|
|
ANTX
AN2 Therapeutics, Inc.
Epetraborole and AN2-502998 are oral small-molecule therapeutics developed on the company's boron chemistry platform.
|
$35.52M |
$1.32
|
|
OKUR
OnKure Therapeutics, Inc.
OKUR operates as a clinical-stage biotech focused on oncology therapies, including mutant-selective PI3Kα inhibitors, directly aligning with Biotech - Oncology.
|
$35.45M |
$2.61
-0.38%
|
|
MURA
Mural Oncology plc
Company develops oncology-focused immunotherapies, including engineered cytokine therapies (nemvaleukin) and related assets.
|
$35.34M |
$2.03
-0.49%
|
|
CELU
Celularity Inc.
Celularity's core products are allogeneic placental-derived cell therapies produced via the IMPACT platform.
|
$34.70M |
$1.31
+4.37%
|
|
DYAI
Dyadic International, Inc.
Company directly produces recombinant proteins and enzymes (e.g., RHSA, transferrin, DNase1, RNase inhibitors, FGF, lactalbumin, lactoferrin) for life sciences, diagnostics, and food/industrial uses.
|
$34.38M |
$0.94
-2.91%
|
|
SIGY
Sigyn Therapeutics, Inc.
Sigyn Therapy is a broad-spectrum blood purification device designed to remove pathogens, toxins, and inflammatory mediators from blood.
|
$34.19M |
$1.00
|
|
RADX
Radiopharm Theranostics Limited
Core product category: Radiopharmaceuticals used for diagnostic imaging and therapy in oncology.
|
$34.00M |
$5.12
+6.78%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Directly markets/provides a proprietary drug-delivery platform (D-MNA) enabling localized chemotherapy delivery.
|
$33.89M |
$1.56
+0.32%
|
|
BDMD
Baird Medical Investment Holdings Limited
BDMD is a medical device manufacturer focused on microwave ablation systems and related hardware, a core medical devices category.
|
$32.97M |
$1.33
+1.14%
|
|
POCI
Precision Optics Corporation, Inc.
The business includes design and manufacture of components/subassemblies for medical devices, i.e., Medical Device Components.
|
$31.94M |
$4.18
-0.59%
|
|
RMTI
Rockwell Medical, Inc.
Rockwell Medical's core offerings are dialysis-related consumables (acid and bicarbonate concentrates, single-use bicarbonate cartridge, and at-home packs) used with dialysis equipment.
|
$31.84M |
$0.93
-1.57%
|
|
RDGL
Vivos Inc.
RDGL's core offering is radiopharmaceutical therapy using Y-90 for targeted cancer treatment.
|
$31.83M |
$0.07
|
|
STCB
Starco Brands, Inc.
Vertical integration via acquisition of The Starco Group provides contract manufacturing capabilities.
|
$31.37M |
$0.04
|
|
NERV
Minerva Neurosciences, Inc.
Minerva focuses on neuropsychiatric drug development (roluperidone for schizophrenia negative symptoms).
|
$31.12M |
$4.50
-4.36%
|
|
BRNS
Barinthus Biotherapeutics plc
Company is pivoting to immunology/inflammation therapeutics and is advancing T‑cell immunotherapies (SNAP-TI), with VTP-1000 for celiac disease as lead candidate.
|
$30.93M |
$0.70
-7.51%
|
|
VNRX
VolitionRx Limited
VolitionRx's Nu.Q platform enables liquid biopsy cancer diagnostics by detecting nucleosome/epigenetic biomarkers in blood.
|
$30.74M |
$0.36
+26.22%
|
|
RLYB
Rallybio Corporation
Core focus on rare diseases with lead and preclinical assets addressing complement dysregulation and iron overload.
|
$29.67M |
$0.73
-1.08%
|
|
ELUT
Elutia Inc.
Elutia's EluPro is a cardiology device used with cardiac implanted electronic devices (CIEDs), directly tying to Cardiology Devices.
|
$29.59M |
$0.70
-0.37%
|
|
BOLD
Boundless Bio, Inc.
The company is a biotechnology firm focused on oncology, developing ecDNA-directed cancer therapies, which places it in Biotech - Oncology.
|
$29.33M |
$1.32
+1.15%
|
|
BTAI
BioXcel Therapeutics, Inc.
BXCL501 is a small-molecule drug delivered as an oral dissolving film; fits 'Oral Small Molecule Therapeutics'.
|
$29.26M |
$2.04
-1.69%
|
Showing page 30 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
